ENDRA Life Sciences Inc.
NDRA
$4.84
-$0.44-8.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -1.04M | -4.15M | -2.35M | -2.23M | -2.78M |
| Total Depreciation and Amortization | 45.60K | 46.40K | 54.00K | 50.10K | 55.70K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -325.50K | 2.38M | 873.80K | 48.50K | 469.00K |
| Change in Net Operating Assets | 23.10K | 211.10K | -230.90K | 47.20K | 106.70K |
| Cash from Operations | -1.29M | -1.52M | -1.66M | -2.08M | -2.14M |
| Capital Expenditure | -17.30K | 0.00 | 0.00 | 11.00K | -27.00K |
| Sale of Property, Plant, and Equipment | -- | 0.00 | 0.00 | 0.00 | 3.20K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -17.30K | 0.00 | 0.00 | 11.00K | -23.80K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 0.00 | 0.00 | 0.00 | -28.50K |
| Issuance of Common Stock | 145.80K | 0.00 | -- | 7.34M | 497.40K |
| Repurchase of Common Stock | -- | -- | -6.69M | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | 6.69M | -- | -- |
| Cash from Financing | 145.80K | 0.00 | 1.70K | 7.34M | 468.90K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | 0.00 | 0.00 | -- | -- |
| Net Change in Cash | -1.16M | -1.52M | -1.66M | 5.27M | -1.70M |